Zymeworks Inc.

Zymeworks Inc. is a biotechnology company focused on developing biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. Its key platforms include the Azymetric multispecific antibody platform, a Drug Conjugate platform with proprietary cytotoxins and linkers, the EFECT platform for Fc region modifications, and the ProTECT tumor-specific immune co-stimulation platform. Lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors, and zanidatamab for neoadjuvant populations, breast cancer, and other HER2-expressing cancers. The pipeline also features Pasritamig (a bispecific T cell engager for prostate cancer), ZW191 (an ADC targeting folate receptor alpha in ovarian, endometrial, and lung cancers), ZW251 (for hepatocellular carcinoma), ZW220 (for NaPi2b-expressing NSCLC and ovarian cancer), ZW209 (a TriTCE targeting Delta-like ligand 3 in solid tumors), and ZW1528 (for chronic obstructive pulmonary disease).

Zymeworks Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ZYME. Its securities trade in United States Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in the United States and operates within the US region, with its stock accessible to investors through major US brokerages.

Zymeworks Inc. operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on research and development of biotherapeutics, specifically leveraging its proprietary platforms to create antibody-based treatments for oncology, inflammation, and autoimmune diseases. This industry involves high-risk, high-reward drug development, with Zymeworks targeting multiple cancer types and other conditions through its diverse pipeline.

Zymeworks Inc. has a robust pipeline of product candidates. The lead candidate is Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors. Zanidatamab is also being developed for neoadjuvant populations, breast cancer, and other HER2-expressing cancers. Pasritamig is a bispecific T cell engager targeting human kallikrein 2 for castration-resistant prostate cancer. The company also has several antibody-drug conjugates (ADCs): ZW191 targets folate receptor alpha in ovarian, endometrial, and non-small cell lung cancers; ZW251 targets glypican 3 in hepatocellular carcinoma; and ZW220 targets NaPi2b in NSCLC and ovarian cancer. Additionally, ZW209 is a novel TriTCE targeting Delta-like ligand 3 in solid tumors, and ZW1528 is a bispecific molecule for chronic obstructive pulmonary disease.

Yes, Zymeworks Inc. has a strategic partnership and collaboration with Jazz Pharmaceuticals plc. This collaboration likely involves co-development or commercialization of certain product candidates, though specific terms are not detailed in the available data. Such partnerships are common in the biotechnology industry to share resources, expertise, and financial risks associated with drug development and commercialization.